High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer.

@article{Qi2012HighWT,
  title={High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer.},
  author={Xiaowei Qi and Fan Zhang and Xin-hua Yang and Lin-jun Fan and Yi Zhang and Yan Liang and Lin Ren and Ling Zhong and Qingqiu Chen and Kongyong Zhang and Weiguo Zang and Li-shan Wang and Ying Zhang and Jun Jiang},
  journal={Oncology reports},
  year={2012},
  volume={28 4},
  pages={
          1231-6
        }
}
The role of Wilms' tumor 1 (WT1) in breast cancer and the relationship between WT1 expression and clinicopathological factors, molecular subtypes and prognosis of breast cancer patients have not been clarified to date. We used publicly available microarray datasets of 266 early breast cancer patients to perform bioinformatics analysis on the relationship between WT1 mRNA expression and breast cancer. Results showed that WT1 mRNA… 
View on PubMed
spandidos-publications.com
26 Citations
Background Citations
9
Results Citations
1

26 Citations

Citation Type

Citation Type

The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism
TLDR
The relationship between Wilms' tumor gene 1 and breast cancer is reviewed, including the relationship between expression of WT1 and prognosis of breast cancer patients, and its effectiveness as a target for comprehensive therapy of Breast cancer.
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis
TLDR
It is suggested that WT1 may be a potential marker to predict DFS/RFS/PFS in solid tumor patients, and further studies are needed to confirm the role of WT1 expression in clinical practice.
Correlation of miR-600 with WT1 expression and its potential clinical significance in breast cancer.
TLDR
The miR-600 acts as tumor suppressor and a diagnostic and prognostic biomarker in breast cancer patients and was correlated with lymph node metastasis and clinical stage.
Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.
TLDR
This first to demonstrate that moderate-to-strong overexpression of WT1 in the cytoplasm of PDA cells is significantly associated with worse OS/DFS times is demonstrated, may impact the recurrence and prognosis of patients with PDA following surgical resection.
Study of WT1 gene expression in human breast cancer
TLDR
The results suggest that WT1(17AA+) may play oncogenic role in breast carcinoma tissues by upregulation of ER- and HER2, but function of WT1 isoforms should be further explored to address the mechanism in breast cancer.
Identification of a Novel Epithelial–Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC
TLDR
A four-EMT-based gene signature is identified which provides the potentiality to serve as novel independent biomarkers for predicting survival in H NSCC patients, as well as a new possibility for individualized treatment of HNSCC.
WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer
TLDR
Expression of WT1 is increased in breast cancers but this is not limited to the vascular compartment, and the association between reduced WT1 in tumour-free tissue and poor prognosis suggests a protective role forWT1 in the healthy breast.
The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.
Wilms’ tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling
TLDR
WT1 exerts a tumor-promoting role in OC, enhancing EMT through negative modulation of E-cadherin expression via ERK1/2 signaling, and may represent a novel therapeutic target that may improve the prognosis of OC.
WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma
TLDR
The data show that WT1 expression in diffuse astrocytic tumours increases with WHO tumour grade and is associated with older age, absence of IDH1 mutation but not related to O(6)- methyl guanine methyl transferase (MGMT) promoter methylation status.
...
1
2
3
...

References

SHOWING 1-10 OF 43 REFERENCES
High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.
  • Y. Miyoshi, A. Ando, +5 authors S. Noguchi
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
It is suggested that measurement of WT1 mRNA levels in tumor tissues might be useful as a new prognostic factor in breast cancer patients, independent of the other conventional prognostic factors.
Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer
TLDR
The results indicate that WT1 expression by tumor is more evident in premenopausal state rather than postmenopausal period, and needs to be confirmed with large scale studies onWT1 expression in breast cancer.
Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation.
Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer.
TLDR
The results indicate that the wild-type WT1 gene plays an important role in the tumorigenesis of primary breast cancer.
Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.
Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
TLDR
This classification and its prognostic effect were validated in 276 luminal A cases from three independent series profiled across different microarray platforms and outperformed the current prognostic factors in univariate and multivariate analyses in both training and validation sets.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
TLDR
Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
TLDR
expression of WT1 in mammary neoplasia is demonstrated, and that WT1 may not have a tumor suppressor role in breast cancer, suggesting other transcriptional regulatory mechanisms appear to supercede its effects in these tumors.
A gene expression signature identifies two prognostic subgroups of basal breast cancer
TLDR
It is suggested that MBC and basal breast cancers share similar molecular alterations associated with aggressiveness, which could help define the prognosis, adapt the systemic treatment, and identify new therapeutic targets.
Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
TLDR
WT1 is expressed in a substantial proportion of HCC contributing to tumor progression and resistance to chemotherapy, suggesting that WT1 may be an important target for HCC treatment.
...
1
2
3
4
5
...